First-Line Bevacizumab (Bev) Combination Therapy in Triple-Negative (TN) Locally Recurrent/Metastatic Breast Cancer (LR/MBC): Subpopulation Analysis of Study MO19391 in >2000 Patients (Pts).

Mapping Intimacies ◽

10.1158/0008-5472.sabcs-09-6093 ◽

2009 ◽

Author(s):

C. Thomssen ◽

J. Pierga ◽

K. Pritchard ◽

L. Biganzoli ◽

H. Cortes-Funes ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Combination Therapy ◽

Triple Negative ◽

Metastatic Breast ◽

Locally Recurrent

Download Full-text

Abstract P2-16-06: Final Overall Survival Results, Including Analysis of Patients with Triple-Negative Disease and Aged ≥70 Years, from the ATHENA Study Evaluating First-Line Bevacizumab-Containing Therapy for Locally Recurrent/Metastatic Breast Cancer

10.1158/0008-5472.sabcs10-p2-16-06 ◽

2010 ◽

Author(s):

KI Pritchard ◽

C Thomssen ◽

J-Y Pierga ◽

H Cortes-Funes ◽

L Biganzoli ◽

...

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Metastatic Breast Cancer ◽

Triple Negative ◽

Metastatic Breast ◽

Locally Recurrent

Download Full-text

P5-19-06: Highly Effective of Gemcitabine and Cisplatin (GP) as First-Line Combination Therapy in Patients with Triple-Negative Metastatic Breast Cancer: Final Report of a Phase II Trial.

10.1158/0008-5472.sabcs11-p5-19-06 ◽

2011 ◽

Author(s):

Z Wang ◽

X Hu ◽

B Wang ◽

L Wang ◽

J Zhang ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Combination Therapy ◽

Phase Ii ◽

Triple Negative ◽

Phase Ii Trial ◽

Metastatic Breast ◽

Final Report ◽

Gemcitabine And Cisplatin

Download Full-text

Abstract P2-16-12: First-Line Bevacizumab Combined with Paclitaxel in Triple-Negative Locally Recurrent/Metastatic Breast Cancer: Subpopulation Analysis of 115 Patients Treated in Routine Oncology Practice in Germany

10.1158/0008-5472.sabcs10-p2-16-12 ◽

2010 ◽

Author(s):

A Schneeweiss ◽

FG Foerster ◽

W Hollburg ◽

H Tesch ◽

P Klare ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Triple Negative ◽

Metastatic Breast ◽

Locally Recurrent ◽

Oncology Practice

Download Full-text

Efficacy of gemcitabine and cisplatin (GP) as first-line combination therapy in patients with triple-negative metastatic breast cancer: Preliminary results report of a phase II trial.

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.1100 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. 1100-1100 ◽

Author(s):

Z. Wang ◽

X. Hu ◽

L. Chen ◽

J. Wang ◽

H. Wang ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Combination Therapy ◽

Phase Ii ◽

Triple Negative ◽

Phase Ii Trial ◽

Metastatic Breast ◽

Preliminary Results ◽

Gemcitabine And Cisplatin

Download Full-text

Efficacy and safety of adding an agent to bevacizumab/taxane regimens for the first-line treatment of Her2-negative patients with locally recurrent or metastatic breast cancer: results from seven randomized controlled trials

OncoTargets and Therapy ◽

10.2147/ott.s103954 ◽

2016 ◽

Vol Volume 9 ◽

pp. 3771-3781 ◽

Author(s):

Xiao-Qun Liu ◽

Xiangdong Liu ◽

Tiankui Qiao ◽

Wei Chen ◽

Sujuan Yuan

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Metastatic Breast ◽

Controlled Trials ◽

Line Treatment ◽

Efficacy And Safety ◽

Randomized Controlled ◽

Locally Recurrent ◽

First Line Treatment

Download Full-text

5074 First-line bevacizumab (bev) plus paclitaxel (pac) combination therapy: safety findings (n = 165) from a multicentre German non-interventional study in patients with metastatic breast cancer (MBC)

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(09)70966-8 ◽

2009 ◽

Vol 7 (2) ◽

pp. 283

Author(s):

F. Foerster ◽

M. Geberth ◽

C. Schumacher ◽

A. Schneeweiss ◽

R. Weinberg ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Combination Therapy ◽

Metastatic Breast ◽

Interventional Study

Download Full-text

nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial

Annals of Oncology ◽

10.1093/annonc/mdy201 ◽

2018 ◽

Vol 29 (8) ◽

pp. 1763-1770 ◽

Author(s):

D.A. Yardley ◽

R. Coleman ◽

P. Conte ◽

J. Cortes ◽

A. Brufsky ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Triple Negative ◽

Metastatic Breast ◽

Line Treatment ◽

First Line Treatment

Download Full-text

Final results from PERUSE, a global study of pertuzumab (P), trastuzumab (H) and investigator’s chosen taxane as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer (LR/mBC)

10.1055/s-0041-1730221 ◽

2021 ◽

Author(s):

A Schneeweiss ◽

D Miles ◽

E Ciruelos ◽

F Puglisi ◽

T Peretz-Yablonski ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Metastatic Breast ◽

Her2 Positive ◽

First Line Therapy ◽

Line Therapy ◽

Global Study ◽

Locally Recurrent

Download Full-text

START: A randomized phase II study in patients with triple negative, androgen receptor positive locally recurrent (unresectable) or metastatic breast cancer treated with darolutamide or capecitabine (UCBG-306)

Annals of Oncology ◽

10.1093/annonc/mdy272.356 ◽

2018 ◽

Vol 29 ◽

pp. viii120 ◽

Author(s):

H. Bonnefoi ◽

C. Levy ◽

G. MacGrogan ◽

T. Grellety ◽

B. Asselain ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Androgen Receptor ◽

Phase Ii ◽

Triple Negative ◽

Phase Ii Study ◽

Metastatic Breast ◽

Randomized Phase Ii ◽

Locally Recurrent

Download Full-text

Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancer

European Journal of Cancer ◽

10.1016/j.ejca.2012.04.022 ◽

2012 ◽

Vol 48 (17) ◽

pp. 3140-3149 ◽

Author(s):

I. Lang ◽

M.J. Inbar ◽

Z. Kahán ◽

R. Greil ◽

S. Beslija ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Metastatic Breast ◽

Phase Iii ◽

Phase Iii Study ◽

Her 2 ◽

Locally Recurrent

Download Full-text